(Q74715799)
Statements
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690 (English)
John M Kirkwood
Thomas Richards
Hassane M Zarour
Jeffrey Sosman
Marc Ernstoff
Theresa L Whiteside
Joseph Ibrahim
Ronald Blum
Samuel Wieand